Table 1.
Prostate cancer patients have preexisting T cells specific for AR LBD-derived peptides
| Patient | Peptide-specific T-cell responses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AR677 | AR700 | AR708 | AR742 | AR761 | AR805 | AR811 | AR814 | AR859 | AR862 | Influenza | |
| D04 | + | − | − | − | − | + | +* | − | − | + | + |
| D05 | − | + | − | − | − | − | − | − | − | − | ns |
| P01 | − | − | + | − | +* | − | +* | − | − | + | + |
| P03 | ns | ns | ns | ns | − | + | − | ns | − | ns | ns |
| P07 | − | + | − | − | + | +* | +* | + | − | + | + |
| P08 | + | + | − | + | + | − | + | + | + | − | + |
| P09 | + | − | + | − | − | − | − | − | + | + | ns |
| P11 | − | − | − | − | − | − | − | − | + | − | + |
| P12 | + | − | − | − | + | + | + | − | − | − | + |
| P16 | − | − | − | − | − | + | − | − | − | − | + |
| P17 | − | − | − | − | + | − | + | − | − | − | + |
| P19 | ns | ns | ns | ns | − | + | + | ns | − | ns | ns |
| P20 | ns | ns | ns | ns | − | − | − | ns | + | ns | ns |
| P21 | ns | ns | ns | ns | + | + | + | ns | − | ns | ns |
| P24 | ns | ns | ns | ns | − | + | − | ns | + | ns | ns |
| Frequency of patients with T-cell responses | 4/10 (40%) | 3/10 (30%) | 2/10 (20%) | 1/10 (10%) | 6/15 (40%) | 8/15 (53%) | 8/15 (53%) | 2/10 (20%) | 5/15 (33%) | 4/10 (40%) | 8/8 (100%) |
AR LBD-derived peptides or an influenza matrix protein positive control were used to culture peptide-specific T cells from as many as fifteen HLA-A2+ patients with prostate cancer (listed in the first column). After 2–8 weekly in vitro peptide stimulations, T-cell cultures raised against individual peptides were tested for the presence of peptide-specific T cells and prostate cancer cell lysis using cytotoxicity assays. Patients from whom peptide-specific CTL could be detected after 2–8 peptide stimulations are indicated with a ‘+’, whereas patients from whom CTL could not be detected are indicated with a ‘−’. Peptides that were not sampled for certain patients are indicated by ‘ns’. Peptide-specific T-cell cultures that were found to lyse prostate cancer cells are indicated by a ‘*’. The frequency of HLA-A2+ prostate cancer patients that recognize each particular peptide is listed in the bottom row